Literature DB >> 23070952

Multifactorial patterns of gene expression in colonic epithelial cells predict disease phenotypes in experimental colitis.

Aubrey L Frantz1, Maria E C Bruno, Eric W Rogier, Halide Tuna, Donald A Cohen, Subbarao Bondada, R Lakshman Chelvarajan, J Anthony Brandon, C Darrell Jennings, Charlotte S Kaetzel.   

Abstract

BACKGROUND: The pathogenesis of inflammatory bowel disease (IBD) is complex and the need to identify molecular biomarkers is critical. Epithelial cells play a central role in maintaining intestinal homeostasis. We previously identified five "signature" biomarkers in colonic epithelial cells (CEC) that are predictive of disease phenotype in Crohn's disease. Here we investigate the ability of CEC biomarkers to define the mechanism and severity of intestinal inflammation.
METHODS: We analyzed the expression of RelA, A20, pIgR, tumor necrosis factor (TNF), and macrophage inflammatory protein (MIP)-2 in CEC of mice with dextran sodium sulfate (DSS) acute colitis or T-cell-mediated chronic colitis. Factor analysis was used to combine the five biomarkers into two multifactorial principal components (PCs). PC scores for individual mice were correlated with disease severity.
RESULTS: For both colitis models, PC1 was strongly weighted toward RelA, A20, and pIgR, and PC2 was strongly weighted toward TNF and MIP-2, while the contributions of other biomarkers varied depending on the etiology of inflammation. Disease severity was correlated with elevated PC2 scores in DSS colitis and reduced PC1 scores in T-cell transfer colitis. Downregulation of pIgR was a common feature observed in both colitis models and was associated with altered cellular localization of pIgR and failure to transport IgA.
CONCLUSIONS: A multifactorial analysis of epithelial gene expression may be more informative than examining single gene responses in IBD. These results provide insight into the homeostatic and proinflammatory functions of CEC in IBD pathogenesis and suggest that biomarker analysis could be useful for evaluating therapeutic options for IBD patients.
Copyright © 2012 Crohn's & Colitis Foundation of America, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23070952      PMCID: PMC3476470          DOI: 10.1002/ibd.22923

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  50 in total

Review 1.  Roundtrip ticket for secretory IgA: role in mucosal homeostasis?

Authors:  Blaise Corthésy
Journal:  J Immunol       Date:  2007-01-01       Impact factor: 5.422

2.  American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006.

Authors:  Michael Clark; Jean-Frederic Colombel; Brian C Feagan; Richard N Fedorak; Stephen B Hanauer; Michael A Kamm; Lloyd Mayer; Carol Regueiro; Paul Rutgeerts; William J Sandborn; Bruce E Sands; Stefan Schreiber; Stephan Targan; Simon Travis; Severine Vermeire
Journal:  Gastroenterology       Date:  2007-07       Impact factor: 22.682

3.  What is principal component analysis?

Authors:  Markus Ringnér
Journal:  Nat Biotechnol       Date:  2008-03       Impact factor: 54.908

4.  Anti tumour necrosis-alpha therapy increases the number of FOXP3 regulatory T cells in children affected by Crohn's disease.

Authors:  Ida Ricciardelli; Keith J Lindley; Marco Londei; Sonia Quaratino
Journal:  Immunology       Date:  2008-04-16       Impact factor: 7.397

5.  Suppression of experimental colitis by intestinal mononuclear phagocytes.

Authors:  Joseph E Qualls; Alan M Kaplan; Nico van Rooijen; Donald A Cohen
Journal:  J Leukoc Biol       Date:  2006-08-03       Impact factor: 4.962

Review 6.  Crohn's disease--defect in innate defence.

Authors:  Michael Gersemann; Jan Wehkamp; Klaus Fellermann; Eduard Friedrich Stange
Journal:  World J Gastroenterol       Date:  2008-09-28       Impact factor: 5.742

7.  Opposing functions of IKKbeta during acute and chronic intestinal inflammation.

Authors:  Lars Eckmann; Tim Nebelsiek; Alexander A Fingerle; Sara M Dann; Jörg Mages; Roland Lang; Sylvie Robine; Martin F Kagnoff; Roland M Schmid; Michael Karin; Melek C Arkan; Florian R Greten
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-24       Impact factor: 11.205

Review 8.  Innate immunity in inflammatory bowel disease: state of the art.

Authors:  Tadakazu Hisamatsu; Haruhiko Ogata; Toshifumi Hibi
Journal:  Curr Opin Gastroenterol       Date:  2008-07       Impact factor: 3.287

Review 9.  Insights from advances in research of chemically induced experimental models of human inflammatory bowel disease.

Authors:  Mayumi Kawada; Atsuko Arihiro; Emiko Mizoguchi
Journal:  World J Gastroenterol       Date:  2007-11-14       Impact factor: 5.742

10.  Isolation and subsequent analysis of murine lamina propria mononuclear cells from colonic tissue.

Authors:  Benno Weigmann; Ingrid Tubbe; Daniel Seidel; Alex Nicolaev; Christoph Becker; Markus F Neurath
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

View more
  11 in total

1.  Secretory antibodies in breast milk promote long-term intestinal homeostasis by regulating the gut microbiota and host gene expression.

Authors:  Eric W Rogier; Aubrey L Frantz; Maria E C Bruno; Leia Wedlund; Donald A Cohen; Arnold J Stromberg; Charlotte S Kaetzel
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-03       Impact factor: 11.205

Review 2.  Cooperativity among secretory IgA, the polymeric immunoglobulin receptor, and the gut microbiota promotes host-microbial mutualism.

Authors:  Charlotte S Kaetzel
Journal:  Immunol Lett       Date:  2014-05-27       Impact factor: 3.685

3.  Modulation of interferon activity-associated soluble molecules by appendicitis and appendectomy limits colitis-identification of novel anti-colitic targets.

Authors:  Rajkumar Cheluvappa; Rajaraman Eri; Annie S Luo; Michael C Grimm
Journal:  J Interferon Cytokine Res       Date:  2014-09-22       Impact factor: 2.607

4.  Correlation of Biomarker Expression in Colonic Mucosa with Disease Phenotype in Crohn's Disease and Ulcerative Colitis.

Authors:  Maria E C Bruno; Eric W Rogier; Razvan I Arsenescu; Deborah R Flomenhoft; Cathryn J Kurkjian; Gavin I Ellis; Charlotte S Kaetzel
Journal:  Dig Dis Sci       Date:  2015-05-09       Impact factor: 3.199

5.  Targeted deletion of MyD88 in intestinal epithelial cells results in compromised antibacterial immunity associated with downregulation of polymeric immunoglobulin receptor, mucin-2, and antibacterial peptides.

Authors:  A L Frantz; E W Rogier; C R Weber; L Shen; D A Cohen; L A Fenton; M E C Bruno; C S Kaetzel
Journal:  Mucosal Immunol       Date:  2012-04-11       Impact factor: 7.313

Review 6.  Glutamine-Induced Secretion of Intestinal Secretory Immunoglobulin A: A Mechanistic Perspective.

Authors:  Wenkai Ren; Kai Wang; Jie Yin; Shuai Chen; Gang Liu; Bie Tan; Guoyao Wu; Fuller W Bazer; Yuanyi Peng; Yulong Yin
Journal:  Front Immunol       Date:  2016-11-24       Impact factor: 7.561

Review 7.  Protective Microbiota: From Localized to Long-Reaching Co-Immunity.

Authors:  Lynn Chiu; Thomas Bazin; Marie-Elise Truchetet; Thierry Schaeverbeke; Laurence Delhaes; Thomas Pradeu
Journal:  Front Immunol       Date:  2017-12-07       Impact factor: 7.561

8.  Impact of Enterobius vermicularis infection and mebendazole treatment on intestinal microbiota and host immune response.

Authors:  Chin-An Yang; Chao Liang; Chia-Li Lin; Chiung-Tzu Hsiao; Ching-Tien Peng; Hung-Chih Lin; Jan-Gowth Chang
Journal:  PLoS Negl Trop Dis       Date:  2017-09-25

Review 9.  IgA and FcαRI: Pathological Roles and Therapeutic Opportunities.

Authors:  Annelot Breedveld; Marjolein van Egmond
Journal:  Front Immunol       Date:  2019-03-22       Impact factor: 7.561

Review 10.  The Role of the Polymeric Immunoglobulin Receptor and Secretory Immunoglobulins during Mucosal Infection and Immunity.

Authors:  Holly Turula; Christiane E Wobus
Journal:  Viruses       Date:  2018-05-03       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.